12/31/2025
Happy New Year — and cheers to 20 years of transforming vascular medicine!
This year marks a major milestone for our company, and as we look back, we’re proud of the innovation, research, and clinical progress we’ve achieved together.
Here are just a few highlights from an extraordinary year:
• Celebrating Our 20th Anniversary •
Two decades of pushing boundaries, partnering with clinicians, and unlocking what’s possible in vascular intervention.
• DynamX BIOADAPTOR RCT 3-Year & INFINITY-SWEDEHEART R-RCT 2-Year Outcomes •
Another strong year of clinical evidence — with long-term RCT data continuing to show improved benefits for patients.
• LithiX Hertz Contact Intravascular Lithotripsy (HC-IVL) Launch •
Expanding the reach of innovative intravascular lithotripsy technology and advancing treatment options for calcification in complex lesions.
• Recognized by Fast Company & Fierce Biotech •
A proud moment as we were honored among the year’s most impactful innovators.
As we turn the page, we’re filled with gratitude for our partners, clinical collaborators, and team members who bring passion and purpose to this mission every day.
Here’s to growth, discovery, collaboration, and progress in 2026.
Wishing you a prosperous and hopeful New Year!
Caution: The DynamX Sirolimus Eluting Coronary Bioadaptor System is an investigational device in the US and limited by federal (or United States) law to investigational use.
LithiX Hertz Contact Lithotripsy System is CE Mark approved and not for sale in the U.S.
